Last reviewed · How we verify

A Single-blind, Multiple Dose, Placebo-controlled, Double Dummy Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

NCT01125514 Phase 2 COMPLETED Results posted

This study assessed the interaction between single and multiple doses of aliskiren (150 mg and 300 mg) and furosemide (60 mg) in patients with heart failure.

Details

Lead sponsorNovartis Pharmaceuticals
PhasePhase 2
StatusCOMPLETED
Enrolment37
Start date2010-05
Completion2011-08

Conditions

Interventions

Primary outcomes

Countries

Germany, Lithuania